Skip to main content
SpringerLink
Log in

Anxiolytics and Sedatives

  • Chapter
  • First Online:
Drug Abuse and Addiction in Medical Illness

  • 4613 Accesses

Abstract

Benzodiazepines are classified as anxiolytics or hypnotics, but the term “sedative” describes a group of drugs, including barbiturates and tricyclic antidepressants as well as benzodiazepines, which are abused. These drugs have different pharmacokinetic characteristics. Patients prescribed benzodiazepines seldom escalate their doses, and primary benzodiazepine abuse is rare. However, secondary abuse of all sedative drugs is common, and high doses are frequently consumed by patients dependent on opiates or alcohol to enhance the effects and by stimulant users to alleviate offset effects after a binge. Benzodiazepines cause dependence on prescribed doses with a clear withdrawal syndrome lasting a few weeks evident in 20–30% patients. The consumption of high doses can result in more severe withdrawal symptoms. Benzodiazepines should never be withdrawn abruptly because of the risk of fits or paranoid psychosis. A stepped care approach to reduction is recommended. All sedative drugs have characteristic pharmacodynamic effects, causing sedation, psychomotor slowing and memory impairment. They increase the risk of accidents and injuries and contribute to specific drug-related harms in abusers. Tolerance develops to some effects but long-term users are impaired compared with non-users. However, gradually stopping the drugs, even after several years of use, results in improvement in functioning, and there is no evidence of lasting impairment or cognitive decline. Newer anxiolytics and SSRIs appear to cause less impairment and have lower abuse potential.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kerr DI, Ong J. GABA-B receptors. Pharmacol Ther. 1995;67:187–246.

    Article  PubMed  CAS  Google Scholar 

  2. Nutt DJ. New insights into the role of the GABA(A)-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry. 2001;179:390–6.

    Article  PubMed  CAS  Google Scholar 

  3. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care—Clinical guidance. http://www.nice.org.uk. 2004.

  4. National Institute for Clinical Excellence. Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guidance 22. http://www.nice.org.uk. 2004.

  5. Mahomed R, et al. Prescribing hypnotics in a mental health trust: what consultants say and what they do. Pharm J. 2002;268:657–9.

    Google Scholar 

  6. Goodwin RD, Hasin DS. Sedative use and misuse in the United States. Addiction. 2001;97:555–62.

    Article  Google Scholar 

  7. Hallstrom C, Lader MH. Benzodiazepine withdrawal phenomena. Int Pharmacopsychiatry. 1981;16:235–44.

    PubMed  CAS  Google Scholar 

  8. Martinez-Cano H, Vela-Bueno A, De Iceta M, Pomalima R, Martinez-Gras I, Sobrino MP. Benzodiazepine types in high versus therapeutic dose dependence. Addiction. 1996;91:1179–86.

    Article  PubMed  CAS  Google Scholar 

  9. De Wit H, Griffiths RR. Testing the abuse liability of anxiolytic and hypnotic drugs in humans. Drug Alcohol Depend. 1991;28:83–111.

    Article  PubMed  Google Scholar 

  10. Seivewright NA, Dougal W. Benzodiazepine misuse. Curr Opin Psychiatry. 1992;5:408–11.

    Article  Google Scholar 

  11. Wolf B, Grohmann R, Biber D, Brenner PM, Ruther E. Benzodiazepine abuse and dependence in psychiatric inpatients. Pharmacopsychiatry. 1989;22:54–60.

    Article  PubMed  CAS  Google Scholar 

  12. Bond AJ, Silveira JC, Lader MH. Effects of single doses of alprazolam alone and alcohol alone and in combination on psychological performance. Hum Psychopharmacol. 1991;6:219–28.

    Article  CAS  Google Scholar 

  13. Peles E, Schreiber S, Adelson M. Tricyclic antidepressants abuse, with or without benzodiazepines abuse, in former heroin addicts currently in methadone maintenance treatment (MMT). Eur Neuropsychopharmacol. 2007;18:188–93.

    Article  PubMed  Google Scholar 

  14. Darke S. Benzodiazepine use among injecting drug users: problems and implications. Addiction. 1994;89:379–82.

    Article  PubMed  CAS  Google Scholar 

  15. Stitzer M, Griffiths R, McLellan A, Grabowski J, Hawthorne J. Diazepam use among methadone maintenance patients: patterns and dosages. Drug Alcohol Depend. 1981;8:189–99.

    Article  PubMed  CAS  Google Scholar 

  16. Sheehan MF, Sheehan DV, Torres A, Coppola A, Francis E. Snorting benzodiazepines. Am J Drug Alcohol Abuse. 1991;17:457–68.

    Article  PubMed  CAS  Google Scholar 

  17. Strang J, Griffiths P, Abbey J, Gossop M. Survey of injected benzodiazepines among drug users in Britain. BMJ. 1994;308:1082.

    Article  PubMed  CAS  Google Scholar 

  18. Bond AJ, Seijas D, Dawling S, Lader MH. Systematic absorption and abuse liability of snorted flunitrazepam. Addiction. 1994;89:821–30.

    Article  PubMed  CAS  Google Scholar 

  19. Launchbury AP, Drake J, Seager H. Misuse of temazepem. BMJ. 1992;305:252–3.

    Article  PubMed  CAS  Google Scholar 

  20. Oliver P, Keen J. Concomitant drugs of misuse and drug using behaviours associated with fatal opiate-related poisonings in Sheffield, UK, 1997-2000. Addiction. 2003;98(2):191–7.

    Article  PubMed  Google Scholar 

  21. Pirnay S, Borron S, Giudicelli C, Tourneau J, Baud F, Ricordel I. A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction. 2004;99:978–88.

    Article  PubMed  CAS  Google Scholar 

  22. Lader M. Withdrawal reactions after stopping hypnotics in patients with insomnia. CNS Drugs. 1998;10:425–40.

    Article  CAS  Google Scholar 

  23. Schweitzer E, et al. Benzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management. Acta Psychiatrica Scand. 1998;393:95–101.

    Article  Google Scholar 

  24. Royal College of Psychiatrists. Benzodiazepines: risks, benefits and dependence: a re-evaluation. Council Report 59. 1997. http://www.rcpsych.ac.uk/(London).

  25. Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19–34.

    Article  PubMed  CAS  Google Scholar 

  26. Voshaar RCO, Couvee JE, Van Balkom AJLM, et al. Strategies for discontinuing long-term benzodiazepine use: meta-analysis. Br J Psychiatry. 2006;189:213–20.

    Article  PubMed  Google Scholar 

  27. Denis C, et al. Pharmacological interventions for mono-dependence benzodiazepine management in outpatient settings. Cochrane Database Syst Rev. 2006;CD005194.

    Google Scholar 

  28. Schweitzer E, et al. Carbamazepine treatment in patients discontinuing long-term benzodiazepine therapy. Effects on withdrawal severity and outcome. Arch Gen Psychiatry. 1991;48:448–52.

    Article  Google Scholar 

  29. Gerra G, Zaimovic A, Giusti F, Moi G, Brewer C. Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomised, placebo-controlled study. Addict Biol. 2002;7:385–95.

    Article  PubMed  CAS  Google Scholar 

  30. Bond AJ, Lader MH, Shotriya R. Comparative effects of a repeated dose regime of diazepam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharm. 1983;24:463–7.

    Article  CAS  Google Scholar 

  31. Curran HV, Collins R, Fletcher S, Kee SCY, Woods B, Iliffe S. Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life. Psychol Med. 2003;33:1223–37.

    Article  PubMed  CAS  Google Scholar 

  32. Darke S, Ross J. The use of antidepressants among injecting drug users in Sydney, Australia. Addiction. 2000;95:407–17.

    Article  PubMed  CAS  Google Scholar 

  33. Woods JH, Katz JL, Winger G. Benzodiazepine use, abuse and consequences. Pharmacol Rev. 1992;44:151–347.

    PubMed  CAS  Google Scholar 

  34. Wittenborn JR, Flaherty CF, McGough WE, Nash RJ. Psychomotor changes during initial day of benzodiazepine medication. Br J Clin Pharmacol. 1979;7:69S–76S.

    Article  PubMed  Google Scholar 

  35. Buffet-Jerrott SE, Stewart SH. Cognitive and sedative effects of benzodiazepine use. Curr Pharm Des. 2002;8:45–58.

    Article  Google Scholar 

  36. Lucki I, Rickels K, Geller AM. Chronic use of benzodiazepines and psychomotor and cognitive test performance. Psychopharmacology. 1986;88:426–33.

    Article  PubMed  CAS  Google Scholar 

  37. Golombok S, Moodley P, Lader M. Cognitive impairment in long-term benzodiazepines users. Psychol Med. 1988;18:365–74.

    Article  PubMed  CAS  Google Scholar 

  38. Petursson H, Gudjonsson G, Lader M. Psychiatric performance during withdrawal form long-term benzodiazepine treatment. Psychopharmacology. 1983;81:345–9.

    Article  PubMed  CAS  Google Scholar 

  39. Curran HV. Benzodiazepines, memory and mood: a review. Psychopharmacology. 1991;105:1–8.

    Article  PubMed  CAS  Google Scholar 

  40. Curran H. Tranquillising memories: a review of the effects of benzodiazepines on human memory. Biol Psychol. 1986;23:179–213.

    Article  PubMed  CAS  Google Scholar 

  41. Curran HV, Gorenstein C. Differential effects of lorazepam and oxazepam on priming. Int Clin Psychopharmacol. 1993;8:37–42.

    Article  PubMed  CAS  Google Scholar 

  42. Curran HV, Bond A, O’Sullivan G, Bruce M, Marks I, Lelliot P, Shine P, Lader M. Memory functions, alprazolam and exposure therapy: a controlled longitudinal trial of agoraphobia with panic disorder. Psychol Med. 1994;24:969–76.

    Article  PubMed  CAS  Google Scholar 

  43. Gorenstein C, Bernik MA, Pompeia S. Differential acute psychomotor and cognitive effects of diazepam on long-term benzodiazepine users. Int Clin Psychopharmacol. 1994;9:145–53.

    Article  PubMed  CAS  Google Scholar 

  44. Barker MJ, Greenwood KM, Jackson M, Crowe SF. Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs. 2004;18:37–48.

    Article  PubMed  CAS  Google Scholar 

  45. Gray S, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf. 1999;21:101–22.

    Article  PubMed  CAS  Google Scholar 

  46. Paterniti S, Dufouil C, Alperovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study. J Clin Psychopharmacol. 2002;22:285–93.

    Article  PubMed  CAS  Google Scholar 

  47. Barker MJ, Greenwood KM, Jackson M, et al. Persistence of ­cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol. 2004;19:437–54.

    Article  PubMed  Google Scholar 

  48. Verdoux H, Lagnaoui R, Begaud B. Is benzodiazepine use a risk factor for cognitive decline and dementia? A literature review of epidemiological studies. Psychol Med. 2005;35:307–15.

    Article  PubMed  Google Scholar 

  49. Salzman C, Fisher J, Nobel K, Glassman R, Wolfson A, Kelley M. Cognitive improvement following benzodiazepine discontinuation in elderly nursing home residents. Int J Geriatr Psychiatry. 1992;7:89–93.

    Article  Google Scholar 

  50. Tata PR, Rollings J, Collins M, Pickering A, Jacobson RR. Lack of cognitive recovery following withdrawal from long-term benzodiazepine use. Psychol Med. 1994;24:203–13.

    Article  PubMed  CAS  Google Scholar 

  51. Kilic C, Curran HV, Noshirvani H, Marks IM, Basoglu M. Long-term effects of alprazolam on memory: a 3.5 year follow-up of agoraphobial panic patients. Psychol Med. 1999;29:225–31.

    Article  PubMed  CAS  Google Scholar 

  52. Wadsworth EJK, Moss SC, Simpson SA, Smith AP. Psychotropic medication use and accidents, injuries and cognitive failures. Hum Psychopharmacol. 2005;20:391–400.

    Article  PubMed  CAS  Google Scholar 

  53. Kallin K, Lundin-Olsson L, Jensen J, Nyberg L, Gustafson Y. Predisposing and precipiataing factors for falls among older people in residential care. Public Health. 2002;116:263–71.

    PubMed  CAS  Google Scholar 

  54. Taylor S, McCracken CF, Wilson KC, et al. Extent and appropriateness of benzodiazepine use. Results from an elderly urban community. Br J Psychiatry. 1998;173:433–8.

    Article  PubMed  CAS  Google Scholar 

  55. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton 3rd LJ. Psychotropic drug use and the risk of hip fracture. New Engl J Med. 1987;316:363–9.

    Article  PubMed  CAS  Google Scholar 

  56. Sternbacka M, Jansson B, Leufman A, Romelsjo A. Association between use of sedatives or hypnotics, alcohol consumption, or other risk factors and single injurious fall or multiple injurious falls: a longitudinal general population study. Alcohol. 2002;28:9–16.

    Article  Google Scholar 

  57. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17:825–37.

    Article  PubMed  CAS  Google Scholar 

  58. O’Hanlon JF, de Gier JJ. Drugs and driving (Taylor and Francis, London, 1986). Addiction. 2003; 98:191–7.

    Google Scholar 

  59. Currie D, Hashemi K, Fothergill J, Findlay A, Harris A, Hindmarch I. The use of antidepressants and benzodiazepines in the perpetrators and victims of accidents. Occup Med. 1995;45:323–5.

    Article  CAS  Google Scholar 

  60. Skegg DCC, Richards SM, Doll R. Minor tranquillisers and road accidents. BMJ. 1979;1:917–9.

    Article  PubMed  CAS  Google Scholar 

  61. Thomas RE. Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician. 1998;44:799–808.

    PubMed  CAS  Google Scholar 

  62. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352:1331–6.

    Article  PubMed  CAS  Google Scholar 

  63. Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27–31.

    Article  PubMed  CAS  Google Scholar 

  64. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol. 1992;136:873–83.

    Article  PubMed  CAS  Google Scholar 

  65. Paton C. Benzodiazepines and disinhibition: a review. Psychiatr Bull. 2002;26:460–2.

    Article  Google Scholar 

  66. Bond AJ. Drug-induced behavioural disinhibition. Incidence, mechanisms and therapeutic implications. CNS Drugs. 1998;9:41–57.

    Article  CAS  Google Scholar 

  67. Preston K, Griffiths R, Cone E, Darwin W, Gorodetzky C. Diazepam and methadone blood levels following concurrent administration of diazepam and methadone. Drug Alcohol Depend. 1986;18:195–202.

    Article  PubMed  CAS  Google Scholar 

  68. Farre M, Teran M, Roset P, Mas M. Abuse liability of flunitrazepam among methadone-maintained patients. Psychopharmacology. 1998;140:486–95.

    Article  PubMed  CAS  Google Scholar 

  69. Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol. 2006;26:274–83.

    Article  PubMed  CAS  Google Scholar 

  70. Lintzeris N, Mitchell TB, Bond AJ, Nestor L, Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug Alcohol Depend. 2007;91:187–94.

    Article  PubMed  CAS  Google Scholar 

  71. Sramek JJ, Tansman M, Suri A, et al. Efficacy of buspirone in generalized anxiety disorder with coexisting mild depressive symptoms. J Clin Psychiatry. 1996;57:287–91.

    PubMed  CAS  Google Scholar 

  72. Lader M. Anxiolytic effect of hydroxyzine: a double-blind trial versus placebo and buspirone. Hum Psychopharmacol. 1999;14 Suppl 1:S94–S102.

    Article  CAS  Google Scholar 

  73. Montgomery SA. Pregabalin for the treatment of generalised anxiety disorder. Expert Opin Pharmacother. 2006;7:2139–54.

    Article  PubMed  CAS  Google Scholar 

  74. National Institute for Clinical Excellence. Insomnia—newer ­hypnotic drugs. Zaleplon,zolpidem and zopiclone for the ­management of insomnia. Technology Appraisal 77. http://www.nice.org.uk. 2004.

  75. Benca RM. Diagnosis and treatment of chronic insomnia: a review. Psychiatr Serv. 2005;56:332–43.

    Article  PubMed  Google Scholar 

  76. Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169.

    Article  PubMed  Google Scholar 

  77. Zisapel N. Development of a melatonin-based formulation for the treatment of insomnia in the elderly. Drug Dev Res. 2000;50:226–34.

    Article  CAS  Google Scholar 

  78. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–5.

    Article  PubMed  CAS  Google Scholar 

  79. Morin CM, Koetter U, Bastien C, et al. Valerian-hops combination and diphenhydramine for treating insomnia: a randomized placebo-controlled clinical trial. Sleep. 2005;28:1465–71.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Addiction, Institute of Psychiatry, King’s College London, London, SE5 8AF, UK

    Alyson Bond

  2. Institute of Psychiatry, Kings College, London, UK

    Malcolm Lader

Authors
  1. Alyson Bond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Malcolm Lader
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alyson Bond .

Editor information

Editors and Affiliations

  1. Inst. Pharmaceutical Sciences, Department of Psychopharmacology, Utrecht University, Universiteitsweg 99, Utrecht, 3584CG, Netherlands

    Joris C. Verster

  2. Dept. Psychiatry, Medical University of South Carolina, President St. 67, Charleston, 29425, South Carolina, USA

    Kathleen Brady

  3. School of Medicine, Div. Alcoholism & Drug Abuse, New York University, First Ave. 550, New York, 10016, New York, USA

    Marc Galanter

  4. Institute of Psychiatry, King's College London, National Addiction Centre, Windsor Walk 4, London, SE5 8AF, United Kingdom

    Patricia Conrod

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Bond, A., Lader, M. (2012). Anxiolytics and Sedatives. In: Verster, J., Brady, K., Galanter, M., Conrod, P. (eds) Drug Abuse and Addiction in Medical Illness. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-3375-0_17

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-3375-0_17

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-3374-3

  • Online ISBN: 978-1-4614-3375-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation